Published in

American Chemical Society, Journal of Medicinal Chemistry, 13(63), p. 7293-7325, 2020

DOI: 10.1021/acs.jmedchem.0c00369

Links

Tools

Export citation

Search in Google Scholar

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models

Journal article published in 2020 by Ulrich Lücking ORCID, Lars Wortmann ORCID, Antje M. Wengner, Julien Lefranc ORCID, Philip Lienau, Hans Briem, Gerhard Siemeister, Ulf Bömer, Karsten Denner, Martina Schäfer, Marcus Koppitz, Knut Eis ORCID, Florian Bartels ORCID, Benjamin Bader, Wilhelm Bone and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Green circle
Preprint: archiving allowed
  • Must obtain written permission from Editor
  • Must not violate ACS ethical Guidelines
Upload
Orange circle
Postprint: archiving restricted
  • Must obtain written permission from Editor
  • Must not violate ACS ethical Guidelines
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO